EZH2 and neoplasm of thorax: Additionally, targeted therapies involving Enhancer of Zeste Homolog 2 (EZH2) inhibitors and histone deacetylase (HDAC) inhibitors have shown promising therapeutic potential in SMARCA4-deficient undifferentiated thoracic tumors (34).